Breast cancer patients diagnosed with clinically positive lymph nodes often receive neoadjuvant systemic therapy (NAST) with the aim to downstage or eradicate the disease. To accurately assess the response in the breast and the axilla, it is important that both the positive lymph node/s and the breast lesion are marked before NAST to be able to locate them later on. Systemic therapy can negatively impact lymphatic drainage and hence reduce the accuracy of the sentinel lymph node biopsy (SLNB). However, when SLNB is paired with removal of the previously positive target lymph node, a technique called Targeted Axillary Dissection (TAD), the operation becomes a lot more accurate. Studies of TAD have demonstrated a false negative rate of < 2 % compared to SLNB alone.
File type:
pdf
File size:
412 KB
Release:
03-11-22
